NCT03071406View on ClinicalTrials.gov

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

April 6, 2022

Study Completion Date

October 31, 2025

Conditions
Merkel Cell CarcinomaSkin Cancer
Interventions
DRUG

Nivolumab

Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.

DRUG

Ipilimumab

Ipilimumab 1 mg/kg/dose IV q6 weeks.

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy 24Gy in 3 fractions.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER